Cellectar CLOVER-WaM trial data accepted for ASCO 2026 poster presentation
PUBT · 04/21 14:01
Share
Listen to the news
- Cellectar Biosciences set a CLOVER-WaM subgroup data update on iopofosine I-131 for presentation at ASCO 2026 on June 1.
- Disclosure targets relapsed or refractory Waldenström macroglobulinemia patients who progressed on BTK inhibitors.
- Management characterized iopofosine safety profile as encouraging.
- Company also described efficacy signals as supportive of a differentiated post-BTK inhibitor option, potentially as early as second-line use.
Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Cellectar BioSciences Inc. published the original content used to generate this news brief via GlobeNewswire (Ref. ID: 202604211000PRIMZONEFULLFEED9693634) on April 21, 2026, and is solely responsible for the information contained therein.
Disclaimer:This article represents the opinion of the author only. It does not represent the opinion of Webull, nor should it be viewed as an indication that Webull either agrees with or confirms the truthfulness or accuracy of the information. It should not be considered as investment advice from Webull or anyone else, nor should it be used as the basis of any investment decision.
What's Trending
No content on the Webull website shall be considered a recommendation or solicitation for the purchase or sale of securities, options or other investment products. All information and data on the website is for reference only and no historical data shall be considered as the basis for judging future trends.
Copyright © 2026 Webull. All Rights Reserved